|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||315.16 - 340.08|
|52-week range||260.25 - 500.92|
|Beta (5Y monthly)||0.71|
|PE ratio (TTM)||61.59|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Genmab (GMAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for hematologic malignancies including NHL and LBCL. A phase I/II study evaluating it in LBCL achieves a response rate of 63%.
Seagen (SGEN) inks a collaboration agreement with Sanofi to develop and commercialize antibody-drug conjugates for three cancer targets.